The provocation broncho-constricting tests in modern pulmonological practice


Cite item

Full Text

Abstract

The provocation broncho-constricting tests are largely applied all over the world with the purpose of diagnostic and differentiated diagnostic of bronchial asthma and chronic obstructive disease of lungs and control of effectiveness of applied therapy. The review presents actual data concerning application of provocation tests in pulmonology.

About the authors

A. L Krasnovskiy

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

Email: alexkras758@yandex.ru
к.м.н., ассистент кафедры внутренних болезней медико-биологического факультета 117997, Moscow, Russia

S. P Grigoriyev

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

д.м.н., профессор, заведующий кафедрой внутренних болезней медико-биологического факультета 117997, Moscow, Russia

O. V Aleksandrov

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

д.м.н., профессор кафедры внутренних болезней медико-биологического факультета 117997, Moscow, Russia

E. O Loshkareva

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

к.м.н., доцент кафедры внутренних болезней медико-биологического факультета 117997, Moscow, Russia

S. A Korviyakov

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

к.м.н., доцент кафедры внутренних болезней медико-биологического факультета 117997, Moscow, Russia

E. S Korotkova

The N.I. Pirogov Russian national research medical university Minzdrav of Russia

к.м.н., доцент кафедры внутренних болезней медико-биологического факультета 117997, Moscow, Russia

References

  1. Чучалин А.Г., ред. Функциональная диагностика в пульмонологии: практическое руководство. М.: Атмосфера; 2009.
  2. Crapo R.O., Casaburi R., Coates A.L., Enright P.L., Hankinson J.L., Irvin C.G. et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am. J. Respir. Crit. Care Med. 2000; 161(1): 309-29.
  3. Busse W.W. The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2. Supp. l): 4S-10S.
  4. Sterk P.J. Airway hyperresponsiveness: using bronchial challenge tests in research and management of asthma. J. Aerosol. Med. 2002; 15(2): 123-9.
  5. Covar R.A. Bronchoprovocation testing in asthma. Immunol. Allergy Clin. North Am. 2007; 27(4): 633-49, vi-vii.
  6. Grootendorst D.C., Rabe K.F. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1(2): 77-87.
  7. Brannan J.D. Bronchial hyperresponsiveness in the assessment of asthma control: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2, Supp. l): 11S-17S.
  8. Cockcroft D.W. Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138 (2, Supp. l): 18S-24S.
  9. Hewitt D.J. Interpretation of the "positive" methacholine challenge. Am. J. Ind. Med. 2008; 51(10): 769-81.
  10. Anderson S.D. Indirect challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2, Supp. l): 25S-30S.
  11. O'Byrne P.M. Introduction: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2, Supp. l): 1S-3S.
  12. Cockcroft D., Davis B. Direct and indirect challenges in the clinical assessment of asthma. Ann. Allergy Asthma Immunol. 2009; 103(5): 363-9.
  13. Gade E., Thomsen S.F., Porsbjerg C., Backer V. The bronchial response to mannitol is attenuated by a previous methacholine test: but not vice versa. Clin. Exp. Allergy. 2009; 39(7): 966-71.
  14. Boulet L.P., Turcotte H., Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest. 1994; 105(4): 1024-31.
  15. Djukanovic R., Wilson J.W., Britten K.M., Wilson S.J., Walls A.F. , Roche W.R. et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. 1992; 145(3): 669-74.
  16. Sont J.K., Han J., van Krieken J.M., Evertse C.E., Hooijer R., Willems L.N. et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996; 51(5): 496-502.
  17. van den Toorn L.M., Overbeek S.E., de Jongste J.C., Leman K., Hoogsteden H.C., Prins J.B. Airway inflammation is present during clinical remission of atopic asthma. Am. J. Respir. Crit. Care Med. 2001; 164(11): 2107-13.
  18. Woolcock A.J., Peat J.K. Epidemiology of bronchial hyperresponsiveness. Clin. Rev. Allergy. 1989; 7(3): 245-56.
  19. Lange P., Parner J., Vestbo J., Schnohr P., Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 19982; 339(17): 1194-200.
  20. Woolcock A.J., Jenkins C.R. Assessment of bronchial responsiveness as a guide to prognosis and therapy in asthma. Med. Clin. North Am. 1990; 74(3): 753-65.
  21. Koenig S.M., Murray J.J., Wolfe J., Andersen L., Yancey S., Prillaman B. et al. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respir. Med. 2008; 102(5): 665-73.
  22. Holgate S.T. The 1992 Cournand Lecture. Asthma: past, present and future. Eur. Respir. J. 1993; 6(10): 1507-20.
  23. Szefler S.J., Leung D.Y.M., eds. Severe Asthma: Pathogenesis and Clinical Management. New York: Marcel Dekker; 1996.
  24. Boulet L.P., Chakir J., Dube J., Laprise C., Boutet M., Laviolette M. Airway inflammation and structural changes in airway hyper-responsiveness and asthma: an overview. Can. Respir. J. 1998; 5(1): 16-21.
  25. Bradley B.L., Azzawi M., Jacobson M., Assoufi B., Collins J.V., Irani A.M. et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 1991; 88(4): 661-74.
  26. Grol M.H., Gerritsen J., Vonk J.M., Schouten J.P., Koeter G.H., Rijcken B. et al. Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study. Am. J. Respir. Crit. Care Med. 1999; 160(6): 1830-7.
  27. van Grunsven P.M., van Schayck C.P., Molema J., Akkermans R.P., van Weel C.Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis. Thorax. 1999; 54(4): 316-22.
  28. Juniper E.F., Kline P.A., Vanzieleghem M.A., Ramsdale E.H., O'Byrne P.M., Hargreave F.E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis. 1990; 142(4): 832-6.
  29. Meijer R.J., Kerstjens H.A., Arends L.R., Kauffman H.F., Koeter G.H. , Postma D.S. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax. 1999; 54(10): 894-9.
  30. Sont J.K., Willems L.N., Bel E. H. et al. Clinical control and histopathologic ontcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am. J. Respir. Crit. Care Med. 1999; 159(4, Pt 1): 1043-51.
  31. Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G. B. et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 2001; 163(2): 406-12.
  32. Hofstra W.B., Neijens H.J., Duiverman E.J., Kouwenberg J.M., Mulder P.G., Kuethe M.C. et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr. Pulmonol. 2000; 29(6): 415-23.
  33. Duong M., Subbarao P., Adelroth E., Obminski G., Strinich T., Inman M. et al. Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. Chest. 2008; 133(2): 404-11.
  34. Gibson P.G., Wlodarczyk J.W., Hensley M.J., Gleeson M., Henry R.L., Cripps A.W. et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am. J. Respir. Crit. Care. Med. 1998; 158(1): 36-41.
  35. Porsbjerg C., Brannan J.D., Anderson S.D., Backer V. Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. Clin. Exp. Allergy. 2008; 38(1): 43-50.
  36. Pedersen S., Hansen O.R. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immunol. 1995; 95(1, Pt 1): 29-33.
  37. Anderson S.D., du Toit J.I., Rodwell L.T., Jenkins C.R. Acute effect of sodium cromoglycate on airway narrowing induced by 4.5 percent saline aerosol. Outcome before and during treatment with aerosol corticosteroids in patients with asthma. Chest. 1994; 105(3): 673-80.
  38. Brannan J.D., Koskela H., Anderson S.D., Chan H.K. Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology. 2002; 7(1): 37-44.
  39. du Toit J.I., Anderson S.D., Jenkins C.R., Woolcock A.J., Rodwell L.T. Airway responsiveness in asthma: bronchial challenge with histamine and 4.5% sodium chloride before and after budesonide. Allergy Asthma Proc. 1997; 18 (1): 7-14.
  40. Chowdhury B.A., Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N. Engl. J. Med. 2010; 362(13): 1169-71.
  41. Porsbjerg C., Lund T.K., Pedersen L., Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J. Asthma. 2009; 46(6): 606-12.
  42. Subbarao P., Duong M., Adelroth E., Otis J., Obminski G., Inman M. et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. 2006; 117(5): 1008-13.
  43. Nuijsink M., Hop W.C., Sterk P.J., Duiverman E.J., de Jongste J. C.Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial. Eur. Respir. J. 2007; 30 (3): 457-66.
  44. Ward C., Pais M., Bish R., Reid D., Feltis B., Johns D. et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002; 57(4): 309-16.
  45. Simpson J.L., Scott R., Boyle M.J., Gibson P.G. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006; 11(1): 54-61.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies